-+ 0.00%
-+ 0.00%
-+ 0.00%

AB Science halts non-priority masitinib trials to focus R&D on AML drug AB8939 and ALS study

PUBT·07/10/2026 15:54:51
Listen to the news
AB Science halts non-priority masitinib trials to focus R&D on AML drug AB8939 and ALS study
  • AB Science halted three non-priority masitinib trials, shifting resources to AB8939 in acute myeloid leukemia, masitinib in amyotrophic lateral sclerosis.
  • Management said the stoppages were not driven by masitinib safety concerns.
  • AB8939 program completed Step 3 of Phase 1 testing AB8939 with venetoclax.
  • Next step targets regulatory clearance to start Step 4 evaluating AB8939 with venetoclax, azacitidine, following a favorable IDMC review.
  • Phase 3 masitinib trial in ALS, authorized in 2025 but not started, will be revised before seeking permission to resume.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AB Science SA published the original content used to generate this news brief on July 10, 2026, and is solely responsible for the information contained therein.